AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 221 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $12,499,000 | -33.8% | 357,111 | +1.1% | 0.01% | -41.2% |
| Q2 2020 | $18,885,000 | -3.7% | 353,117 | -36.1% | 0.02% | -29.2% |
| Q1 2020 | $19,611,000 | -25.1% | 552,729 | +0.8% | 0.02% | -7.7% |
| Q4 2019 | $26,184,000 | +48.7% | 548,353 | +0.9% | 0.03% | +36.8% |
| Q3 2019 | $17,613,000 | -40.9% | 543,604 | -9.1% | 0.02% | -36.7% |
| Q2 2019 | $29,820,000 | +14.9% | 597,839 | +55.3% | 0.03% | +15.4% |
| Q1 2019 | $25,957,000 | +190.9% | 384,890 | +98.9% | 0.03% | +160.0% |
| Q4 2018 | $8,924,000 | -40.8% | 193,531 | -0.9% | 0.01% | -28.6% |
| Q3 2018 | $15,067,000 | -7.8% | 195,370 | +0.7% | 0.01% | -12.5% |
| Q2 2018 | $16,335,000 | +4.7% | 193,935 | +1.7% | 0.02% | 0.0% |
| Q1 2018 | $15,600,000 | +64.1% | 190,752 | +14.7% | 0.02% | +77.8% |
| Q4 2017 | $9,505,000 | -14.3% | 166,255 | +0.1% | 0.01% | -18.2% |
| Q3 2017 | $11,085,000 | +29.4% | 166,065 | -0.2% | 0.01% | +22.2% |
| Q2 2017 | $8,564,000 | -13.6% | 166,455 | -2.0% | 0.01% | -18.2% |
| Q1 2017 | $9,916,000 | +39.9% | 169,799 | 0.0% | 0.01% | +37.5% |
| Q4 2016 | $7,086,000 | -20.7% | 169,799 | +0.3% | 0.01% | -20.0% |
| Q3 2016 | $8,940,000 | +25.5% | 169,252 | -0.4% | 0.01% | +25.0% |
| Q2 2016 | $7,121,000 | -63.6% | 169,974 | -64.7% | 0.01% | -61.9% |
| Q1 2016 | $19,573,000 | -29.9% | 482,097 | +12.1% | 0.02% | -22.2% |
| Q4 2015 | $27,921,000 | +148.9% | 430,085 | +170.6% | 0.03% | +145.5% |
| Q3 2015 | $11,220,000 | -36.1% | 158,943 | +0.6% | 0.01% | -31.2% |
| Q2 2015 | $17,554,000 | +18.8% | 157,949 | +0.8% | 0.02% | +14.3% |
| Q1 2015 | $14,775,000 | -15.6% | 156,677 | +0.3% | 0.01% | -12.5% |
| Q4 2014 | $17,509,000 | +20.2% | 156,277 | -34.2% | 0.02% | +14.3% |
| Q3 2014 | $14,566,000 | +34.0% | 237,425 | +0.1% | 0.01% | +40.0% |
| Q2 2014 | $10,870,000 | -10.3% | 237,239 | -23.3% | 0.01% | -16.7% |
| Q1 2014 | $12,113,000 | +64.6% | 309,407 | +0.7% | 0.01% | +71.4% |
| Q4 2013 | $7,358,000 | +50.4% | 307,235 | +75.6% | 0.01% | +40.0% |
| Q3 2013 | $4,893,000 | – | 175,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |